CCR researchers show selumetinib shrinks tumors in children with NF1

Findings from a phase 2 clinical trial show that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis type 1 (NF1). In the trial, selumetinib shrank the inoperable tumors that develop with NF1 called plexiform neurofibromas, and children experienced reduced pain, improved function, and better overall quality of life after receiving the treatment. This trial was led by Brigitte Widemann, M.D., Chief of the Pediatric Oncology Branch (POB), and Andrea M. Gross, M.D., Assistant Research Physician in POB, and the results were published March 18, 2020, in the New England Journal of Medicine. Read more...

CCR researchers show selumetinib shrinks tumors in children with NF1
Molecular transporter that helps to assemble the machinery for cellular power generation

Researchers identify protein essential for assembling cells’ energy-producing machine

Feb 12, 2020

CCR researchers have discovered that the protein Bcs1 acts as the element that facilitates the transport of iron-sulfur protein, or ISP, across the inner membranes of mitochondria, the cell’s power plant. ISP is needed for the assembly of Complex III, a key element of the respiratory chain, which ensures that nutrients are converted to ATP, energy that cells need. Read more...

HPV structure

New tool catalogs thousands of previously unknown viruses

Feb 4, 2020

In the quest to study two cancer-causing viruses, a team of researchers has uncovered a wealth of previously unknown viruses, some with very unusual properties. The work could one day help identify viruses associated with cancer and other disease. Read more...

James Kochenderfer

James N. Kochenderfer receives Top Ten Clinical Research Achievement Award

Feb 3, 2020

James N. Kochenderfer, M.D., Investigator in the Surgery Branch, has been named a Top Ten Clinical Research Achievement Awardee by the Clinical Research Forum. Dr. Kochenderfer received the award for “Development of CAR T-Cell Therapy for Myeloma.” Read more...

Bladder cancer scan

Clinical trial tests combination immunotherapy for genitourinary tumors

Jan 29, 2020

Andrea B. Apolo, M.D., of the Genitourinary Malignancies Branch, is leading a study to recruit patients with each of the nearly 40 rare genitourinary malignancies and treat them with a combination of chemotherapy and immunotherapy drugs.  Read more...

TP53 model

T-cell stimulation could be used to target cancers with common TP53 gene mutations

Jan 29, 2020

Researchers in the Center for Cancer Research have found that circulating lymphocytes can be stimulated in the laboratory to generate cells that can recognize TP53 gene mutations. Mutations to the TP53 gene are found in about 40 percent of all cancers, making this process a potentially significant step forward in fighting many types of cancer. Read more...

HeLa cell

New technology elucidates how metabolites interact with proteins to drive cancer

Jan 24, 2020

Acyl-coenzyme As (CoAs) are a group of small molecule metabolites that are the building blocks and chemical energy source for all living organisms. Recent evidence indicates that metabolites such as acyl-CoAs can also interact with proteins to drive the development of cancer. Read more...

CAR T-cell therapy

Side effects of CAR T-cell therapy are dramatically reduced with new receptor

Jan 22, 2020

A new immunotherapy for lymphoma has been found to cause lower levels of neurologic toxicity than other T-cell therapies for lymphoma. The findings come from the first clinical test of a CAR T-cell therapy using a new anti-cancer T-cell receptor developed in the Center for Cancer Research. Read more...

lung cancer metastasis

Now recruiting: Combination therapy clinical trial for small-cell lung or small-cell extrapulmonary cancers

Jan 16, 2020

Anish Thomas, M.D., of the Developmental Therapeutics Branch, is leading a study of a drug combination to treat small-cell lung cancer that has come back after treatment as well as small-cell cancer that started at a site other than the lungs (extrapulmonary). Small-cell lung cancer is an aggressive, fast-growing type of lung cancer. Read more...

Non-small cell lung cancer

Genomic profiles of lung cancer differ based on ancestry

Jan 14, 2020

An analysis of tumors from people with non-small cell lung cancer by researchers at the Center for Cancer Research revealed differences in genomic instability and homologous recombination deficiency in tumors from people with African ancestry compared to those with European ancestry. These findings highlight ancestry-related differences in tumor biology and may help improve our understanding of the higher incidence of cancer burden and high mortality observed in African Americans. Read more...

Marijo Bilusic

Clinical trial investigates IV administration of vaccine for advanced solid tumors

Jan 14, 2020

Marijo Bilusic, M.D., Ph.D., of the Genitourinary Malignancies Branch, is leading a clinical trial to test whether giving the MVA-BN-brachyury vaccine intravenously is safe for humans and has no intolerable side effects. The goal of the study is to see whether intravenous MVA-BN-brachyury vaccine can shrink tumors and slow or prevent the spread of cancer to other parts of the body. Read more...

Pages